Arbutus Biopharma (ABUS) Revenue (2009 - 2026)
Arbutus Biopharma recorded quarterly Revenue of $179.1 million in Q1 2026, up 16943.39% quarter-over-quarter from $1.1 million in Q4 2025, and up 10054.54% year-over-year from N/an in Q1 2025.
Arbutus Biopharma's Revenue history runs 18 years deep, the most recent figure standing at $179.1 million for Q1 2026.
- In Q1 2026, Revenue rose 10054.54% year-over-year to $179.1 million; the TTM figure through Mar 2026 stood at $191.4 million (up 2889.93% YoY), while the FY2025 annual figure was $14.1 million, up 128.21% from the prior year.
- Revenue came in at $179.1 million for Q1 2026 at Arbutus Biopharma, up from $1.1 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $179.1 million in Q1 2026 to a low of $529000.0 in Q3 2025.
- A 5-year average of $15.1 million and a median of $4.7 million in 2023 frame the typical range for Revenue.
- Across the five-year window, Revenue sank 77.09% in 2024 and soared 10054.54% in 2026, its largest moves.
- Arbutus Biopharma's Revenue stood at $6.2 million in 2022, then sank by 65.65% to $2.1 million in 2023, then fell by 26.62% to $1.6 million in 2024, then plunged by 33.23% to $1.1 million in 2025, then soared by 16943.39% to $179.1 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $179.1 million, $1.1 million, and $529000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Arbutus Biopharma | 883.58 Mn | 883.58 Mn | - | 179.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 179.13 Mn |
| Dec 31, 2025 | 1.05 Mn |
| Sep 30, 2025 | 529,000.00 |
| Jun 30, 2025 | 10.74 Mn |
| Mar 31, 2025 | 1.76 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.53 Mn |
| Dec 31, 2023 | 2.15 Mn |
| Sep 30, 2023 | 4.66 Mn |
| Jun 30, 2023 | 4.65 Mn |
| Mar 31, 2023 | 6.69 Mn |
| Dec 31, 2022 | 6.25 Mn |
| Sep 30, 2022 | 5.95 Mn |
| Jun 30, 2022 | 14.24 Mn |
| Mar 31, 2022 | 12.58 Mn |
| Dec 31, 2021 | 3.21 Mn |
| Sep 30, 2021 | 3.34 Mn |
| Jun 30, 2021 | 2.33 Mn |
| Mar 31, 2021 | 2.11 Mn |
| Dec 31, 2020 | 2.39 Mn |
| Sep 30, 2020 | 1.52 Mn |
| Jun 30, 2020 | 1.51 Mn |
| Mar 31, 2020 | 1.49 Mn |
| Dec 31, 2019 | 1.62 Mn |
| Sep 30, 2019 | 3.06 Mn |
| Jun 30, 2019 | 653,000.00 |
| Mar 31, 2019 | 679,000.00 |
| Dec 31, 2018 | 1.68 Mn |
| Sep 30, 2018 | 1.59 Mn |
| Jun 30, 2018 | 1.24 Mn |
| Mar 31, 2018 | 1.44 Mn |
| Dec 31, 2017 | 2.53 Mn |
| Sep 30, 2017 | 6.89 Mn |
| Jun 30, 2017 | 1.04 Mn |
| Mar 31, 2017 | 235,000.00 |
| Dec 31, 2016 | 195,000.00 |
| Sep 30, 2016 | 774,000.00 |
| Jun 30, 2016 | 309,000.00 |
| Mar 31, 2016 | 603,000.00 |
| Dec 31, 2015 | 12.69 Mn |
| Sep 30, 2015 | 4.07 Mn |
| Jun 30, 2015 | 3.44 Mn |
| Mar 31, 2015 | 4.68 Mn |
| Dec 31, 2014 | 4.35 Mn |
| Sep 30, 2014 | 4.36 Mn |
| Jun 30, 2014 | 1.81 Mn |
| Mar 31, 2014 | 4.43 Mn |
| Dec 31, 2013 | 752,000.00 |
| Sep 30, 2013 | 2.96 Mn |
| Jun 30, 2013 | 2.84 Mn |
| Mar 31, 2013 | 2.13 Mn |
| Dec 31, 2012 | 3.94 Mn |
| Sep 30, 2012 | 3.06 Mn |
| Jun 30, 2012 | 3.59 Mn |
| Mar 31, 2012 | 3.60 Mn |
| Dec 31, 2011 | 3.70 Mn |
| Sep 30, 2011 | 4.29 Mn |
| Jun 30, 2011 | 4.55 Mn |
| Mar 31, 2011 | 4.36 Mn |
| Dec 31, 2010 | 6.12 Mn |
| Sep 30, 2010 | 3.80 Mn |
| Jun 30, 2010 | 2.24 Mn |
| Mar 31, 2010 | 2.40 Mn |
| Dec 31, 2009 | 4.26 Mn |
| Sep 30, 2009 | 3.01 Mn |